TBPMF - Tetra Bio-Pharma inks amended license pact with IntelGenx for mucoadhesive delivery technology

IntelGenx ([[IGXT]] +4.9%) has entered into an amended and restated license agreement granting Tetra Bio-Pharma ([[TBPMF]] +5.6%) additional worldwide exclusive rights for the mucoadhesive delivery technology for its PPP-002 (Dronabinol) drug candidate.In addition to the Dronabinol Soft Gel capsules, a cannabinoid-derived prescription drug aimed at treating AIDS-related anorexia and severe nausea linked with chemotherapy, Tetra will advance a second cannabinoid derived medicine utilizing IntelGenx's Adversa technology, for patients who suffer nausea while having chemotherapy.According to the agreement, Tetra will buy the Adversa technology which can be applied to its Dronabinol drug franchise, for three undisclosed milestones: 45% to be paid on November 15; 45% to be paid on March 1, 2021, and a final payment of 10% upon successful technology transfer.In addition, Tetra will pay IntelGenx a low single digit royalty on future net sales of Dronabinol mucoadhesive tablets.Last month, Tetra Bio-Pharma announced to acquire exclusive distribution rights in Canada for Dronabinol Soft Gel.

For further details see:

Tetra Bio-Pharma inks amended license pact with IntelGenx for mucoadhesive delivery technology